KDR and small cell lung carcinoma: Anlotinib is also a small-molecule TKI targeting VEGFR, FGFR, PDGFR, and C-KIT.185 It was evaluated in a phase II study for the efficacy as a third or subsequent line treatment compared with placebo in SCLC.